View in EDS

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.

Saved in:
Bibliographic Details
Title: Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Authors: Gligorov, J.1 joseph.gligorov@aphp.fr, Ataseven, B.2, Verrill, M.3, De Laurentiis, M.4, Jung, K.H.5, Azim, H.A.6, Al-Sakaff, N.7, Lauer, S.8, Shing, M.9, Pivot, X.10
Source: European Journal of Cancer. Sep2017, Vol. 82, p237-246. 10p.
Database: Academic Search Ultimate
Description
ISSN:09598049
DOI:10.1016/j.ejca.2017.05.010